Key result
APOA1 gene polymorphisms show no significant association with dyslipidemia in a Kazakh population.
Why the study?
The potential association between APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) and dyslipidemia in the Kazakh population of Xinjiang was unclear.
Are APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) associated with dyslipidemia in the Kazakh population?
Case-Control (n=736)
Are APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) associated with dyslipidemia in the Kazakh population?
Polymorphisms in the APOA1 gene (rs670, rs5069, and rs2070665) are not significantly associated with dyslipidemia in the Kazakh population of Xinjiang.
Suggests potential genetic markers for dyslipidemia in Kazakhs; hypothesis-generating and should not yet alter clinical practice.
The aim of this study was to investigate the potential association between apolipoprotein A1 (APOA1) gene rs670, rs5069, and rs2070665 polymorphisms and dyslipidemia in the Kazakh population of Xinjiang, China. Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) was used to identify APOA1 (rs670, rs5069, and rs2070665) genotypes in 736 subjects (341 dyslipidemia patients and 395 control subjects). The frequencies of the CC genotype for rs1421085 were found to be 7.2% (obese group), 4.4% (overweight group), and 5.6% (control group). Polymorphisms of the three loci of the APOA1 gene in Kazakh subjects met Hardy-Weinberg equilibrium. The frequencies of the A allele for rs670 were found to be 14.3% (dyslipidemia group) and 12.7% (control group). The frequencies of the T allele for rs5069 and rs2070665 were: dyslipidmia group (7.2 and 30.1%, respectively) and control group (7.7 and 32.5%, respectively). Frequency distributions of the 3 types of genotypes and alleles of the three loci showed no statistically significant difference (P > 0.05). Significant differences were observed in lipoprotein (α) [Lp(α)] between patients with the rs2070665 CT + TT and CC genotypes (P < 0.05); however, none of the other relevant indicators differed significantly between the two genotypes. No significant association was identified between rs670 or rs5069 and the lipid-related metabolic indices assessed in the study. These findings indicate that the polymorphisms in the APOA1 gene (rs670, rs5069, and rs2070665) are not associated with dyslipidemia in the Kazakh population assessed in this study.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2016) conducted a case-control in Dyslipidemia (n=736). APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) vs. Control subjects (without dyslipidemia) was evaluated on Dyslipidemia (p=> 0.05). APOA1 gene polymorphisms (rs670, rs5069, and rs2070665) were not significantly associated with dyslipidemia in the Kazakh population (P > 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Lipid managementMore from Genetics and Molecular Research